Global Small Animal Imaging Market - 2022-2029

Market Overview

The global small animal imaging market size was valued US$ YY million in 2021 and is expected to reach US$ YY million by 2029, growing at a CAGR of 7% during the forecast period (2022-2029).

Small animal imaging is a molecular imaging technique that explores in vivo characterization and quantification of biological processes at the cellular and molecular levels. These techniques monitor and record the spatiotemporal distribution of molecular or cellular processes directly or indirectly for biochemical, biological, diagnostic, or therapeutic applications. The equipment used in small animal imaging is similar to those used in human diagnostics; however, due to their small size, they are referred to as microdevices.

Market Dynamics

The global market for small animal imaging is primarily driven by growing demand for small animal imaging techniques, technological advancement in the field of small animal imaging, and rising investment in developing new diagnostic and therapeutic devices.

Technological advancement in small animal imaging techniques for monitoring mouse tumor regression is expected to drive market growth.

Assessing the effectiveness of cancer therapeutics in mouse models is a critical step in treatment development. However, low-resolution measurement tools and small sample sizes make determining drug efficacy in vivo difficult and time-intensive. Therefore, a commercially scalable wearable electronic strain sensor automates the in vivo testing of cancer therapeutics by continuously monitoring the micrometer-scale progression or regression of subcutaneously implanted tumors. Moreover, within 5 hours of starting medication, the sensor detects changes in tumor volume dynamics between drug- and vehicle-treated tumors in in-vivo cancer mouse models. In addition, this sensor achieves three main advances over other common tumor measurement tools such as calipers, implantable pressure sensors, and imagers. Thus, real-time tumor regression datasets will assist in speeding up and automating cancer treatment screening in vivo.

Stringent regulatory approvals for molecular imaging devices by government initiatives are expected to hamper market growth.

The clinical feasibility of molecular imaging devices depends on FDA approval of imaging probes and funding from insurance companies and the Centers for Medicare and Medicaid Services (CMS). Because molecular imaging devices are associated with many probes and technologies, the total approval procedure is extensive, complicated, and costly. Thus, from the above factors, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

During the COVID-19 pandemic, it has brought attention to the necessity of animal research in developing safe and effective vaccines. The developments have also paved the way for new working methods, such as a greater emphasis on bioinformatics and enhanced data sharing. The requirement for research and development operations during the COVID-19 epidemic enhanced the availability and manufacture of imaging products. Therefore, the above factors have impacted positively the growth of the global small-animal imaging market.

Segment Analysis

Biodistribution Studies segment is estimated to hold the largest market share in small animal imaging market.

The biodistribution studies segment accounted for the largest market share in 2021. The segment benefits because, when analyzing therapeutic efficacy, it is critical to examine the drug-target interaction of novel compounds or preclinical bio-distribution to optimize drug formulations and find acceptable profiles. Therefore, non-invasive near-infrared (NIR) fluorescence imaging allows real-time monitoring and detection of a novel drug's whole-body tissue biodistribution. Thus, from the above factors, the market segment is accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global small animal imaging market

North America accounted for the largest market share in 2021. Growing demand for technologically advanced methods, vast preclinical research, established healthcare infrastructure, and favorable platform for R&D to technological advancements are the factors to drive the market in the forecast period. For instance, The development and usage of multimodal instruments, both in the preclinical and clinical phases, is rapidly increasing as technology evolves. Dual-modality or hybrid PET/CT scanners are preferred devices for clinical nuclear medicine; SPECT/CT scanners are now frequently utilized for routine analysis. The benefit of these multimodal instruments is their ability to combine the functional strength of one technology, like SPECT and PET, with the high-resolution anatomical imaging provided by CT or MRI. Recent technological advances in preclinical in-vivo modalities include PET/CT, PET/MRI, and SPECT/CT.

Moreover, PerkinElmer, Inc. released the IVIS Lumina S5 and X5 high throughput benchtop 2D optical in vivo imaging systems. These two innovative systems provide researchers with a fluid workflow to facilitate the diagnosis of illness development and to help advance treatments for a wide range of infectious diseases, malignancies, and other disorders by leveraging smart accessory design, hardware, and software advancements. Therefore, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

key players in the small animal imaging market are: Life Technologies Corporation, Thermo Fisher Scientific, PerkinElmer, Inc, Siemens AG, Bruker Corporation, Aspect Imaging Ltd., Promega Corporation, Trifoil Imaging, Miltenyi Biotec GmbH and MR solutions Ltd.

In April 2022, Hallmarq Veterinary Imaging announced that the Veterinary Emergency and Referral Center (VERC) in Hawaii had deployed its 1.5T small animal MRI system.

PerkinElmer, Inc.:

Overview:

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation. PerkinElmer, Inc. provides products and services, and solutions for diagnostics, life sciences, and applied services markets. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Diagnostics segment includes instruments, reagents, assay platforms, and software for the early detection of genetic disorders, such as pregnancy and early childhood, and infectious disease testing in the diagnostics market. Company's products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The segment also develops technologies that enable and support genomic workflows using protein-coupled receptors and next-generation DNA sequencing for oncology and drug discovery applications. Moreover, the company provides products to laboratories, academic and research institutions, pharmaceutical and biotechnology companies, , public health authorities, private healthcare organizations, doctors, and government agencies.

Product Portfolio:

IVIS Spectrum In Vivo Imaging System: The IVIS Spectrum in vivo imaging system combines 2D optical and 3D optical tomography in single platform. The system utilizes innovative optical technology for preclinical imaging research and development, ideal for non-invasive longitudinal monitoring of disease progression, gene expression patterns in living animals, and cell trafficking.

Key Developments:

On April 25, 2022, PerkinElmer, Inc. launched the Vega imaging system, which expands its in vivo imaging range. This unique ultrasonic platform combines hands-free, automated technology with the high-throughput capability to speed non-invasive research and drug discovery investigations in cancer, liver and kidney disease, cardiology, and other fields.

The global small animal imaging market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.